Wolfgang Miesbach: Cognitive Impairment in aPL-Positive Patients
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
“Cognitive impairment in aPL-positive patients.
An important presentation by Gustavo Balbi and colleagues on the real-world recognition and management of cognitive impairment in patients with antiphospholipid antibodies (aPL).
Clinicians most frequently associated aPL with depression, anxiety, impaired attention, slower processing speed, and memory or executive dysfunction.
Yet routine cognitive screening remains uncommon – particularly in patients without stroke and TIA or overt symptoms.
Stronger collaboration between APS specialists, cognitive neurologists, and neuropsychologists is urgently needed to improve recognition, assessment, and care.”
Other posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Sep 19, 2026, 10:52Consuela A. Albright: The Critical Role of Black Blood Donors in Sickle Cell Treatment
-
Sep 19, 2026, 10:47Amber Yates: Inside Agios’ Partnership with the Sickle Cell Community
-
Sep 19, 2026, 10:46Anton Farkas: Mechanical Thrombectomy for Acute PE in Early Pregnancy
-
Sep 19, 2026, 10:40Marjolein Smidt: ASH Raises Ferritin Thresholds for Iron Deficiency
-
Sep 19, 2026, 10:34Nawsherwan Mohammad: ASH 2026 Guidelines Redefine How We Detect Iron Deficiency
-
Sep 19, 2026, 10:21Upcoming Podcast on Thalassaemia with The Lancet Haematology
-
Sep 19, 2026, 10:20Steve Helm: Cardiology and Anticoagulation Pharmacist Role Opens Near NYC
-
Sep 19, 2026, 10:12Omid Seidizadeh: A Great Pleasure to Speak on vWD at the 59th NordCoag Congress
-
Sep 19, 2026, 10:08Carsten Hansen: What Happens During a Sickle Cell Crisis?